They discussed in surrounding Marja that we were largely through the clearing phase and more rapidly moving to a phase of hold, which puts a premium obviously on good governance.
In some ways it is like a biotech company doing all it can to hold things together to bring a promising new drug through trials to Phase III testing before selling it off to a major with the sacks of money to bring it to market.